[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100598361":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":30,"collaborators":11,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":11,"eligibilityCriteria":39,"healthyVolunteers":36,"sex":40,"minAge":41,"maxAge":11,"enrollmentInfo":42,"targetDuration":11,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":11,"overallStatus":52,"whyStopped":11,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":11},{"fullName":5,"class":6},"Sutter Health","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Vivity Extended Depth of Focus IOL","EXPERIMENTAL",null,[13,14],"Device: cataract surgery","Procedure: retinal surgery",{"label":16,"type":17,"description":11,"interventionNames":18},"Standard monofocal IOL","ACTIVE_COMPARATOR",[13,14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DEVICE","cataract surgery","cataract surgery receiving Vivity IOL or standard mono focal controls",[16,9],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"PROCEDURE","retinal surgery","Retinal surgery for visually significant epiretinal membrane",[16,9],{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"SPONSOR_INVESTIGATOR","Debbie Kuo, MD","Palo Alto Foundation Medical Group affiliated Ophthalmologist","100598361","outcomes-of-combined-cataract-surgery-with-retinal-surgery-for-visually-significant-epiretinal-membrane-with-vivity-versus-monofocal-intraocular-lens-100598361",false,"NCT07070492","Outcomes of Combined Cataract Surgery With Retinal Surgery for Visually Significant Epiretinal Membrane With Vivity Versus Monofocal Intraocular Lens","Inclusion Criteria:\n\n* Adult patients with visually significant epiretinal membrane who are undergoing or have already had pars plana vitrectomy and membrane peel combined with cataract surgery using Clareon Vivity and Clareon Vivity Toric IOLs or monofocal IOL\n* IOL powers between +6D to +30.0D, T3-T6\n\nExclusion Criteria:\n\n* History of ocular or refractive surgery\n* Other ocular or systemic comorbidities that may alter or reduce visual acuity and contrast sensitivity, such as severe dry eye\u002Focular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, strabismus\u002Famblyopia etc.\n* Patients with irregular astigmatism, corneal dystrophies, pupil abnormalities, zonular laxity\n* Intraoperative or postoperative complications","ALL","18 Years",{"count":43,"type":44},36,"ESTIMATED","INTERVENTIONAL",[47],"NA","To investigate the patient Quality of Life and satisfaction outcomes of combined cataract surgery with retinal surgery for visually significant epiretinal membrane in patients receiving Vivity IOL versus standard monofocal controls.",[50,51],"Cataract and IOL Surgery","Epi-retinal Membrane","NOT_YET_RECRUITING","2025-07-07",{"date":55,"type":56},"2025-07-17","ACTUAL",{"date":58,"type":44},"2025-07",{"date":60,"type":44},"2027-07",{"name":32,"class":6}]